alendronate has been researched along with ezetimibe in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Connolly, JG; Gagne, JJ | 1 |
1 review(s) available for alendronate and ezetimibe
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for alendronate and ezetimibe
| Article | Year |
|---|---|
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States | 2016 |